Immuneering (NASDAQ:IMRX) Stock Rating Lowered by Wall Street Zen

Immuneering (NASDAQ:IMRX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

IMRX has been the subject of several other reports. Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Chardan Capital reissued a “buy” rating and issued a $20.00 price target on shares of Immuneering in a research note on Tuesday, May 19th. Cantor Fitzgerald started coverage on Immuneering in a report on Wednesday, July 8th. They issued an “overweight” rating and a $17.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Immuneering presently has a consensus rating of “Moderate Buy” and an average price target of $17.57.

Immuneering Stock Performance

Shares of IMRX opened at $4.46 on Monday. The stock has a fifty day moving average of $4.80 and a two-hundred day moving average of $5.09. The company has a market capitalization of $288.56 million, a PE ratio of -3.81 and a beta of 0.41. Immuneering has a fifty-two week low of $2.90 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. As a group, equities research analysts forecast that Immuneering will post -1.09 earnings per share for the current fiscal year.

Institutional Trading of Immuneering

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Empery Asset Management LP purchased a new position in Immuneering in the fourth quarter valued at approximately $17,601,000. State Street Corp grew its stake in Immuneering by 1,289.7% during the fourth quarter. State Street Corp now owns 2,402,238 shares of the company’s stock worth $15,807,000 after buying an additional 2,229,374 shares during the period. Vanguard Group Inc. increased its position in shares of Immuneering by 128.5% in the third quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after acquiring an additional 1,358,322 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Immuneering in the third quarter worth $6,602,000. Finally, Marshall Wace LLP raised its stake in shares of Immuneering by 162.4% in the 4th quarter. Marshall Wace LLP now owns 711,875 shares of the company’s stock valued at $4,684,000 after acquiring an additional 440,571 shares during the period. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.